CD90/Thy-1, a Cancer-Associated Cell Surface Signaling Molecule

Chloé Sauzay; Konstantinos Voutetakis; Aristotelis Chatziioannou; Eric Chevet; Tony Avril

doi:10.3389/fcell.2019.00066

CD90/Thy-1, a Cancer-Associated Cell Surface Signaling Molecule

Front Cell Dev Biol. 2019 Apr 26:7:66. doi: 10.3389/fcell.2019.00066. eCollection 2019.

Authors

Chloé Sauzay^{1

2}, Konstantinos Voutetakis^{3

4}, Aristotelis Chatziioannou^{3

5}, Eric Chevet^{1

2

6}, Tony Avril^{1

2

6}

Affiliations

¹ INSERM U1242, Proteostasis and Cancer Team, Chemistry Oncogenesis Stress Signaling, Université de Rennes 1, Rennes, France.
² Centre Eugène Marquis, Rennes, France.
³ Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece.
⁴ Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
⁵ e-NIOS Applications PC, Kallithea-Athens, Greece.
⁶ Rennes Brain Cancer Team (REACT), Rennes, France.

Abstract

CD90 is a membrane GPI-anchored protein with one Ig V-type superfamily domain that was initially described in mouse T cells. Besides the specific expression pattern and functions of CD90 that were described in normal tissues, i.e., neurons, fibroblasts and T cells, increasing evidences are currently highlighting the possible involvement of CD90 in cancer. This review first provides a brief overview on CD90 gene, mRNA and protein features and then describes the established links between CD90 and cancer. Finally, we report newly uncovered functional connections between CD90 and endoplasmic reticulum (ER) stress signaling and discuss their potential impact on cancer development.

Keywords: CD90; ER stress; IRE1; THY-1; cancer; invasion; migration.

Publication types

Review